BerGenBio ASA (OSL:BGBIO)

Norway flag Norway · Delayed Price · Currency is NOK
1.148
-0.002 (-0.17%)
Aug 15, 2025, 4:19 PM CET
-0.17%
Market Cap44.87M
Revenue (ttm)848.00K
Net Income (ttm)-139.28M
Shares Out39.09M
EPS (ttm)-3.95
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume145,934
Average Volume138,249
Open1.280
Previous Close1.150
Day's Range1.122 - 1.280
52-Week Range1.020 - 15.670
Beta1.20
RSI41.35
Earnings DateAug 20, 2025

About BerGenBio ASA

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory disease in Norway. It develops BGBIL025, a JAK2 inhibitor indicated, which is in Ph1b/2a for treatment of the bone marrow disorder myelofibrosis. The company was incorporated in 2007 and is based in Bergen, Norway. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2007
Employees 13
Stock Exchange Oslo Børs
Ticker Symbol BGBIO
Full Company Profile

Financial Performance

In 2024, BerGenBio ASA's revenue was 848,000, an increase of 139.55% compared to the previous year's 354,000. Losses were -139.28 million, -26.85% less than in 2023.

Financial Statements

News

BerGenBio ASA (STU:7BG0) Q4 2024 Earnings Call Highlights: Strategic Review and Financial ...

BerGenBio ASA (STU:7BG0) Q4 2024 Earnings Call Highlights: Strategic Review and Financial Management in Focus

6 months ago - GuruFocus